BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Thanki K, Blum KG, Thakur A, Rose F, Foged C. Formulation of RNA interference-based drugs for pulmonary delivery: challenges and opportunities. Ther Deliv 2018;9:731-49. [PMID: 30277138 DOI: 10.4155/tde-2018-0029] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Bardoliwala D, Patel V, Javia A, Ghosh S, Patel A, Misra A. Nanocarriers in effective pulmonary delivery of siRNA: current approaches and challenges. Ther Deliv 2019;10:311-32. [PMID: 31116099 DOI: 10.4155/tde-2019-0012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
2 Piyush R, Rajarshi K, Chatterjee A, Khan R, Ray S. Nucleic acid-based therapy for coronavirus disease 2019. Heliyon 2020;6:e05007. [PMID: 32984620 DOI: 10.1016/j.heliyon.2020.e05007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
3 Jamalkhah M, Asaadi Y, Azangou-Khyavy M, Khanali J, Soleimani M, Kiani J, Arefian E. MSC-derived exosomes carrying a cocktail of exogenous interfering RNAs an unprecedented therapy in era of COVID-19 outbreak. J Transl Med 2021;19:164. [PMID: 33888147 DOI: 10.1186/s12967-021-02840-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Thanki K, van Eetvelde D, Geyer A, Fraire J, Hendrix R, Van Eygen H, Putteman E, Sami H, de Souza Carvalho-Wodarz C, Franzyk H, Nielsen HM, Braeckmans K, Lehr CM, Ogris M, Foged C. Mechanistic profiling of the release kinetics of siRNA from lipidoid-polymer hybrid nanoparticles in vitro and in vivo after pulmonary administration. J Control Release 2019;310:82-93. [PMID: 31398360 DOI: 10.1016/j.jconrel.2019.08.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
5 Thakur A, Foged C. Nanoparticles for mucosal vaccine delivery. Nanoengineered Biomaterials for Advanced Drug Delivery. Elsevier; 2020. pp. 603-46. [DOI: 10.1016/b978-0-08-102985-5.00025-5] [Cited by in Crossref: 9] [Article Influence: 4.5] [Reference Citation Analysis]
6 Conte G, Costabile G, Baldassi D, Rondelli V, Bassi R, Colombo D, Linardos G, Fiscarelli EV, Sorrentino R, Miro A, Quaglia F, Brocca P, d'Angelo I, Merkel OM, Ungaro F. Hybrid Lipid/Polymer Nanoparticles to Tackle the Cystic Fibrosis Mucus Barrier in siRNA Delivery to the Lungs: Does PEGylation Make the Difference? ACS Appl Mater Interfaces 2022;14:7565-78. [PMID: 35107987 DOI: 10.1021/acsami.1c14975] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Zoulikha M, Xiao Q, Boafo GF, Sallam MA, Chen Z, He W. Pulmonary delivery of siRNA against acute lung injury/acute respiratory distress syndrome. Acta Pharm Sin B 2022;12:600-20. [PMID: 34401226 DOI: 10.1016/j.apsb.2021.08.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
8 Kubczak M, Michlewska S, Bryszewska M, Aigner A, Ionov M. Nanoparticles for local delivery of siRNA in lung therapy. Adv Drug Deliv Rev 2021;179:114038. [PMID: 34742826 DOI: 10.1016/j.addr.2021.114038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Ponkshe P, Feng S, Tan C. Inhalable liposomes for treating lung diseases: clinical development and challenges. Biomed Mater 2021;16. [PMID: 34134097 DOI: 10.1088/1748-605X/ac0c0c] [Reference Citation Analysis]
10 Keil TW, Merkel OM. Dry powder inhalation of siRNA. Ther Deliv 2019;10:265-7. [PMID: 31094296 DOI: 10.4155/tde-2019-0018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
11 Rodrigues TB, Petrick JS. Safety Considerations for Humans and Other Vertebrates Regarding Agricultural Uses of Externally Applied RNA Molecules. Front Plant Sci 2020;11:407. [PMID: 32391029 DOI: 10.3389/fpls.2020.00407] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 5.5] [Reference Citation Analysis]
12 de Braganca L, Ferguson GJ, Luis Santos J, Derrick JP. Adverse immunological responses against non-viral nanoparticle (NP) delivery systems in the lung. J Immunotoxicol 2021;18:61-73. [PMID: 33956565 DOI: 10.1080/1547691X.2021.1902432] [Reference Citation Analysis]